SMMT
Summit Therapeutics shares advance after updated Phase III cancer trial results (NASDAQ:SMMT)
Article Summary
HOLD- Summit Therapeutics Inc. (NASDAQ: SMMT) gained 3% after releasing updated overall survival data from its global Phase III HARMONi trial evaluating ivonescimab in combination with chemotherapy for advanced lung cancer, with patients treated in Western countries achieving an overall survival hazard ratio of 0.76, matching the outcome previously reported in the Asian patient population.
- The study enrolled patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer whose disease had progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor.
- Updated results showed median follow-up period of 23.2 months for Western patients significantly longer than the 9.2-month median for Asian patients, with median overall survival reaching 16.8 months for patients receiving ivones cimab plus chemotherapy compared with 14.0 months for those treated with placebo alongside chemotherapy.
- Summit Therapeutics submitted updated survival analysis to the U.S.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 0.0% | 25% | 20.0 ptsMinimal (0.0%) - Very weak |
| EPS Growth Next 5Y ? | 30.3% | 25% | 90.0 ptsExcellent (30.3%) - Strong outlook |
| Target Price Upside ? | 98.7% | 20% | 100.0 ptsMassive Upside (98.7%) - Target: $29.84 vs Current: $15.02 |
| Gross Margin % ? | — | 15% | 40.0 ptsNo Gross Margin Data |
| Drawdown from 52-Wk High ? | -51.5% | 15% | 100.0 ptsDeep Discount (-51.5%) - Best entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About SMMT
- Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
- Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
- The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC.
- It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa.
- The company was founded in 2003 and is headquartered in Miami, Florida.